ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

  1. 学内発行雑誌
  2. The Showa University journal of medical sciences
  3. Vol.30(2018)
  4. No.2

Efficacy and Safety of Long-acting Beta-2 Agonist and Long-acting Muscarinic Antagonist Combinations in Patients with Chronic Obstructive Pulmonary Disease: Meta-analysis of Phase 3 Randomized Trials

https://showa.repo.nii.ac.jp/records/465
https://showa.repo.nii.ac.jp/records/465
1b778491-b05d-4604-a8b2-41d3d8d3249d
名前 / ファイル ライセンス アクション
S30_159.pdf S30_159.pdf (1.3 MB)
Item type 学内発行雑誌 / Departmental Bulletin Paper(1)
公開日 2018-09-03
タイトル
タイトル Efficacy and Safety of Long-acting Beta-2 Agonist and Long-acting Muscarinic Antagonist Combinations in Patients with Chronic Obstructive Pulmonary Disease: Meta-analysis of Phase 3 Randomized Trials
言語
言語 eng
資源タイプ
資源タイプ departmental bulletin paper
著者 ANDO, Koichi

× ANDO, Koichi

ANDO, Koichi

Search repository
TANAKA, Akihiko

× TANAKA, Akihiko

TANAKA, Akihiko

Search repository
KUSUMOTO, Sojiro

× KUSUMOTO, Sojiro

KUSUMOTO, Sojiro

Search repository
YAMAOKA, Toshimitsu

× YAMAOKA, Toshimitsu

YAMAOKA, Toshimitsu

Search repository
OHMORI, Tohru

× OHMORI, Tohru

OHMORI, Tohru

Search repository
OHNISHI, Tsukasa

× OHNISHI, Tsukasa

OHNISHI, Tsukasa

Search repository
INOUE, Shin

× INOUE, Shin

INOUE, Shin

Search repository
SAGARA, Hironori

× SAGARA, Hironori

SAGARA, Hironori

Search repository
書誌情報 The Showa University journal of medical sciences

巻 30, 号 2, p. 159-174, 発行日 2018-06
抄録
内容記述タイプ Abstract
内容記述 The aim of the present study was to assess the overall efficacy and safety of long-acting beta-2 agonist (LABA) and long-acting muscarinic antagonist (LAMA) combination therapies (LABA/LAMA) versus monotherapies or placebo in patients with chronic obstructive pulmonary disease (COPD). The overall efficacy and safety of LABA/LAMA versus LABA, LAMA, or placebo in patients with COPD were assessed by meta-analysis of Phase 3 trials. Primary efficacy outcomes included changes in forced expiratory volume in 1 second (FEV10) from baseline and responder rates using St. George’s Respiratory Questionnaire (SGRQ). The incidence of serious adverse events (SAEs) was the primary safety outcome. Pooled estimates are presented as standard mean differences (SMD), odds ratios (ORs), or risk differences (RDs) with 95% confidence intervals (CIs). Eleven articles reporting on 13 randomized controlled trials of LABA/LAMA met the criteria for inclusion in the present study. Comparing LABA/LAMA with LAMA, LABA, and placebo, the SMD (95% CI) for a change in FEV10 from baseline was 0.08 (0.06-0.09), 0.09 (0.07-0.11), and 0.24 (0.19-0.30), respectively; the corresponding ORs (95% CI) for changes in SGRQ score were 1.39 (1.24-1.57), 1.39 (1.06-1.83), and 1.80 (1.47-2.19), respectively. The RDs (95% CIs) for SAEs with LABA/LAMA compared with LAMA, LABA, and placebo were −0.01 (−0.02, 0.00), −0.01 (−0.03, 0.00), and 0.01 (−0.01, 0.02), respectively. Pulmonary function and health-related quality of life were significantly higher for LABA/LAMA, and the risk of SAEs did not increase significantly with combination therapy. These results indicate the overall efficacy and safety of LABA/LAMA in patients with COPD.
DOI
関連識別子 10.15369/sujms.30.159
出版者
出版者 Showa University Society
ISSN
収録物識別子 0915-6380
出版タイプ
出版タイプ VoR
戻る
0
views
See details
Views

Versions

Ver.1 2023-05-15 12:46:18.542922
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR 2.0
  • OAI-PMH JPCOAR 1.0
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3